Navigation

Asthma (in children) - corticosteroids

Corticosteroids for the treatment of chronic asthma in children under the age of 12 years

Status: History
Expected date of issue: November 2007
Process: MTA
Description:


Topic area:
  • Respiratory
 

NICE project team

Executive Lead: Andrea Sutcliffe
Technical Lead: Zoe Garrett
Communications manager: Phil Ranson
Project manager: Eloise Saile
Assessment Group / Evidence Review Group: Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: December 2005
Information meeting with consultees: 28 April 2006
Closing date for invited submissions / evidence submission: 26 July 2006
Final scope published: February 2006
1st appraisal committee meeting: 26 April 2007
2nd appraisal committee meeting: 27 June 2007
Top


 

Consultees and commentators

Consultees Commentators (no right of appeal)

Manufacturers / Sponsors

  • Altana Pharma Ltd
  • AstraZeneca UK Ltd
  • GlaxoSmithKline UK Ltd
  • Ranbaxy UK Limited
  • Trinity-Chiesi Pharmaceuticals Ltd
  • Viatris Pharmaceuticals Ltd

Patient / Carer Groups

  • Action Against Allergy (AAA)
  • Action for Sick Children
  • Allergy UK
  • Asthma UK
  • WellChild

Professional Groups

  • British Paediatric Respiratory Society
  • British Thoracic Society
  • Cochrane Airways Group
  • Education for Health
  • General Practice Airways Group (GPIAG)
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Paediatrics and Child Health
  • Royal College of Physicians
  • Royal College of Physicians of Edinburgh
  • Royal Pharmaceutical Society

Others

  • Department of Health
  • Knowsley PCT
  • Welsh Assembly Government

General

  • British National Formulary
  • Medicines and Healthcare products    Regulatory Agency (MHRA)
  • NHS Confederation
  • NHS Quality Improvement Scotland

Comparator Manufacturers

  • AstraZeneca UK Ltd
  • GlaxoSmithKline UK Ltd
  • IVAX Pharmaceuticals UK Ltd
  • Merck Pharmaceuticals Ltd
  • Merck, Sharp & Dohme Ltd (leukotriene receptor antagonists)
  • Napp Pharmaceuticals Ltd (oral theophyllines)
  • Ranbaxy UK Limited
  • TEVA UK Ltd
  • Trinity-Chiesi Pharmaceuticals Ltd
  • Viatris Pharmaceuticals Ltd

Assessment Team

  • National Coordinating Centre for Health Technology Assessment
  • Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Associated Guideline Groups

  • None

Associated Public Health Groups

  • None

Research Groups

  • Asthma And Allergy Research Group, University of Dundee
  • Respiratory Research Group, University of Glasgow

Top


 

Project history

Date Update
8 June 2005 Topic summary published.
16 March 2006 Final matrix of consultees published.
25 August 2006 List of stakeholders updated.
10 January 2007 List of stakeholders updated.
Top


 

Key documents

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.